Cannabis is an increasingly popular and controversial drug used worldwide. Cannabis use often begins during adolescence, a highly susceptible period for environmental stimuli to alter functional and structural organization of the developing brain. Given that adolescence is a critical time for the emergence of mental illnesses before fullonset in early adulthood, it is particularly important to investigate how genetic insults and adolescent cannabis exposure interact to affect brain development and function. Here we show for the first time that a perturbation in disrupted in schizophrenia 1 (DISC1) exacerbates the response to adolescent exposure to delta-9-tetrahydrocannabinol (Δ 9 -THC), a major psychoactive ingredient of cannabis, consistent with the concept that gene-environment interaction may contribute to the pathophysiology of psychiatric conditions. We found that chronic adolescent treatment with Δ 9 -THC exacerbates deficits in fear-associated memory in adult mice that express a putative dominant-negative mutant of DISC1 (DN-DISC1). Synaptic expression of cannabinoid receptor 1 (CB1R) is down-regulated in the prefrontal cortex, hippocampus, and amygdala, critical brain regions for fearassociated memory, by either expression of DN-DISC1 or adolescent Δ 9 -THC treatment. Notably, elevation of c-Fos expression evoked by context-dependent fear memory retrieval is impaired in these brain regions in DN-DISC1 mice. We also found a synergistic reduction of c-Fos expression induced by cue-dependent fear memory retrieval in DN-DISC1 with adolescent Δ 9 -THC exposure. These results suggest that alteration of CB1R-mediated signaling in DN-DISC1 mice may underlie susceptibility to detrimental effects of adolescent cannabis exposure on adult behaviors.
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Introduction
Most psychiatric illnesses, including schizophrenia, have complex etiologies involving multiple genetic risk factors that may interact with detrimental environmental factors across the lifespan (Caspi and Moffitt, 2006) . Accumulating evidence indicates that adolescence is a susceptible period during which environmental stimuli alter developing functions and structures of maturing neural circuitry, contributing to the onset of psychiatric conditions, such as schizophrenia in early adulthood (Insel, 2010; Jaaro-Peled et al., 2009 ).
Cannabis use during adolescence is one such environmental factor for the development of psychosis (Bossong and Niesink, 2010; Rubino and Parolaro, 2008; Saito et al., 2013) . Cannabis users during adolescence have an increased risk for psychotic disorders such as schizophrenia, in comparison to non-cannabis consumers (Andreasson et al., 1987; Arseneault et al., 2002; Henquet et al., 2005; van Os et al., 2002) . In addition, the prevalence of first break psychosis and prodromal symptoms of psychosis is higher for adolescent cannabis users (Di Forti et al., 2009; Leeson et al., 2012; Miettunen et al., 2008) . Notably, with the decriminalization and even legalization of marijuana in several countries, including the United States, usage has become more commonplace, outpacing even tobacco consumption among adolescents (Johnston et al., 2014) . Nonetheless, not all cannabis users develop psychosis, suggesting that there may be a genetic predisposition interacting with adverse effects of cannabis. Consistently, preclinical studies showed that mice with genetic mutation in catechol-O-methyltransferase (COMT) and neuregulin 1, genetic risk factors for psychiatric conditions, Neurobiology of Disease 82 (2015) 176-184 
